Suven Life Sciences Ltd will be presenting the pre-clinical data of their promising lead compounds, 5-HT 6 antagonists in the annual meeting of the Society for Neuroscience (SFN) to be held at the Georgia World Congress Centre, in Atlanta, GA., from October 14-18, 2006.

The highly selective small molecule drug candidates, 5-HT 6 antagonists, is being developed for the treatment of mild cognitive impairment (MCI) associated with Alzheimer's disease or Schizophrenia, Parkinson and Obesity diseases.

"We are encouraged by the results of these pre-clinical studies which lead us to believe that these selected 5HT6 antagonists may provide a novel, safe and effective approach of treating diseases like MCI, Alzheimer's, Schizophrenia, Parkinson's and obesity" says Venkat Jasti, CEO of the company. The company has a number of programmes in each of these areas, focusing on novel approaches that may hold promise for the development of new therapies for patients.

Neuroscience is the annual meeting of the Society for Neuroscience (SFN). More than 30,000 scientists from all over the world will attend this year meeting. Neuroscience 2006, the Society's 36th annual meeting. Every year the Society for Neuroscience provides the premier venue for neuroscientists around the world to share their research findings.